Survival of lung cancer patients remains poor despite increasingly aggressive treatment.
Conventional staging has well-described limitations. 18F-FDG PET has been shown to …

After potentially curative therapy of non–small cell lung cancer (NSCLC), masses or
symptoms suggestive of relapse are common but may be difficult to characterize. Early …

Purpose Our objective was to determine the impact of initial 18 F-FDG PET/CT (PET/CT)
staging on clinical stage and the management plan and the prognostic value of PET/CT in …

We investigated the incremental management impact and prognostic value of staging with
18F-FDG PET/CT in patients with non–small cell lung cancer (NSCLC) being considered for …

Objective To investigate whether differences in thoracic tumour staging between 18 F-FDG
PET/CT and PET/MR imaging lead to different therapeutic decisions in Non-Small Cell Lung …

BACKGROUND Successful treatment of nonsmall cell lung carcinoma (NSCLC) with radical
radiotherapy (RT) requires accurate delineation of tumor extent. Conventional computed …

Therapeutic decisions in non–small cell lung cancer (NSCLC) patients depend on the tumor
stage. PET/CT with 18F-FDG is widely accepted as the diagnostic standard of care. The …

The integral role of positron-emission tomography (PET) using the glucose analog tracer
fluorine-18 fluorodeoxyglucose (FDG) in the staging of non-small cell lung cancer (NSCLC) …

The purpose of this study was to evaluate the value of an 18F-FDG PET/CT–based
interpretation system (Hopkins criteria) to assess the therapy response and survival in lung …

PURPOSE: To prospectively study the impact of 18F fluorodeoxyglucose (FDG) positron
emission tomography (PET) on clinical management of patients with non–small-cell lung …